Skip to content
2000
Volume 15, Issue 4
  • ISSN: 2210-3031
  • E-ISSN: 2210-304X

Abstract

Cancer remains one of the most significant global health challenges, necessitating innovative therapeutic approaches to improve treatment efficacy and minimize side effects. Traditional methods such as chemotherapy, radiotherapy, and surgery, while effective to some extent, face limitations, including drug resistance, tumor recurrence, and systemic toxicity. In this context, microbial-based nanoparticles have emerged as a novel and promising solution in cancer therapy. These nanoparticles leverage the inherent properties of microbes, such as targeting and biocompatibility, in combination with nanotechnology to deliver drugs with precision, enhance bioavailability, and reduce off-target effects.

This review highlights recent advancements in microbial-derived nanoparticles, focusing on their mechanisms of action, such as immune modulation, tumor penetration, and drug delivery capabilities. Furthermore, it discusses their potential to overcome current therapeutic challenges, emphasizing safety, efficacy, and scalability. Microbial-based nanoparticles offer a pathway toward more patient-centered and precision-based therapeutic solutions by addressing critical gaps in existing cancer treatments. The review also explores the challenges of clinical translation, such as toxicity concerns, regulatory hurdles, and manufacturing complexities, while providing insights into future research directions to accelerate their application in clinical practice.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ddl/10.2174/0122103031324481250609130704
2025-06-24
2026-02-26

  • From This Site

    /content/journals/ddl/10.2174/0122103031324481250609130704
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. ZhuC. JiZ. MaJ. DingZ. ShenJ. WangQ. Recent advances of nanotechnology-facilitated bacteria-based drug and gene delivery systems for cancer treatment.Pharmaceutics202113794010.3390/pharmaceutics1307094034202452
     [Google Scholar]
  2. BascuasT. MorenoM. GrilleS. ChabalgoityJ.A. Salmonella immunotherapy improves the outcome of CHOP chemotherapy in non-Hodgkin lymphoma-bearing mice.Front. Immunol.20189710.3389/fimmu.2018.0000729410666
     [Google Scholar]
  3. EbeltN.D. ManuelE.R. Utilizing Salmonella to treat solid malignancies.J. Surg. Oncol.20171161758210.1002/jso.2464428420039
     [Google Scholar]
  4. XieY.J. HuangM. LiD. HouJ.C. LiangH.H. NasimA.A. HuangJ.M. XieC. LeungE.L.H. FanX.X. Bacteria-based nanodrug for anticancer therapy.Pharmacol. Res.202218210628210.1016/j.phrs.2022.10628235662630
     [Google Scholar]
  5. TorchilinV.P. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery.Nat. Rev. Drug Discov.2014131181382710.1038/nrd433325287120
     [Google Scholar]
  6. KlibanovA.L. MaruyamaK. TorchilinV.P. HuangL. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes.FEBS Lett.1990268123523710.1016/0014‑5793(90)81016‑H2384160
     [Google Scholar]
  7. MessagerL. BurnsJ.R. KimJ. CecchinD. HindleyJ. PyneA.L.B. GaitzschJ. BattagliaG. HoworkaS. Biomimetic hybrid nanocontainers with selective permeability.Angew. Chem. Int. Ed.20165537111061110910.1002/anie.20160467727560310
     [Google Scholar]
  8. KievitF.M. ZhangM. Surface engineering of iron oxide nanoparticles for targeted cancer therapy.Acc. Chem. Res.2011441085386210.1021/ar200027721528865
     [Google Scholar]
  9. DvirT. BanghartM.R. TimkoB.P. LangerR. KohaneD.S. Photo-targeted nanoparticles.Nano Lett.201010125025410.1021/nl903411s19904979
     [Google Scholar]
  10. XieS. ChenM. SongX. ZhangZ. ZhangZ. ChenZ. LiX. Bacterial microbots for acid-labile release of hybrid micelles to promote the synergistic antitumor efficacy.Acta Biomater.20187819821010.1016/j.actbio.2018.07.04130036720
     [Google Scholar]
  11. NguyenV.H. KimH.S. HaJ.M. HongY. ChoyH.E. MinJ.J. Genetically engineered Salmonella typhimurium as an imageable therapeutic probe for cancer.Cancer Res.2010701182310.1158/0008‑5472.CAN‑09‑345320028866
     [Google Scholar]
  12. MintonNP Clostridia in cancer therapy.Nat. Rev. Microbiol.2003123724210.1038/nrmicro777
     [Google Scholar]
  13. WeiM.Q. MengeshaA. GoodD. AnnéJ. Bacterial targeted tumour therapy-dawn of a new era.Cancer Lett.20082591162710.1016/j.canlet.2007.10.03418063294
     [Google Scholar]
  14. MoralesA. EidingerD. BruceA.W. Intracavitary bacillus calmette-guerin in the treatment of superficial bladder tumors.J. Urol.1976116218018210.1016/S0022‑5347(17)58737‑6820877
     [Google Scholar]
  15. ShintaniY. SawadaY. InagakiT. KohjimotoY. UekadoY. ShinkaT. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: Study of the mechanism of bacillus Calmette-Guérin immunotherapy.Int. J. Urol.200714214014610.1111/j.1442‑2042.2007.01696.x17302571
     [Google Scholar]
  16. VictorTorres CarlosOlivar Luis CarlaNavarro JorgeFuenmayor AdriánPérez AndresMindiola MilagrosRojas SofíaMartínez María ManuelVelasco JoselynRojas Bacteria in cancer therapy: beyond immunostimulation.J. Cancer Metastasis Treat.20184410.20517/2394‑4722.2017.49
     [Google Scholar]
  17. DattaN.R. OrdóñezS.G. GaiplU.S. PaulidesM.M. CrezeeH. GellermannJ. MarderD. PuricE. BodisS. Local hyperthermia combined with radiotherapy and-/or chemotherapy: Recent advances and promises for the future.Cancer Treat. Rev.201541974275310.1016/j.ctrv.2015.05.00926051911
     [Google Scholar]
  18. Al-HiluS.A. Al-ShujairiW.H. Dual role of bacteria in carcinoma: Stimulation and inhibition.Int. J. Microbiol.2020202011510.1155/2020/463976132908523
     [Google Scholar]
  19. SarotraP. MedhiB. Use of bacteria in cancer therapy.Recent Results Cancer Res.201620911112110.1007/978‑3‑319‑42934‑2_828101691
     [Google Scholar]
  20. SongS. VuaiM.S. ZhongM. The role of bacteria in cancer therapy – Enemies in the past, but allies at present.Infect. Agent. Cancer2018131910.1186/s13027‑018‑0180‑y
     [Google Scholar]
  21. DiazL.A.Jr CheongI. FossC.A. ZhangX. PetersB.A. AgrawalN. BettegowdaC. KarimB. LiuG. KhanK. HuangX. KohliM. DangL.H. HwangP. VogelsteinA. Garrett-MayerE. KobrinB. PomperM. ZhouS. KinzlerK.W. VogelsteinB. HusoD.L. Pharmacologic and toxicologic evaluation of C. novyi-NT spores.Toxicol. Sci.200588256257510.1093/toxsci/kfi31616162850
     [Google Scholar]
  22. AgrawalN. BettegowdaC. CheongI. GeschwindJ.F. DrakeC.G. HipkissE.L. TatsumiM. DangL.H. DiazL.A.Jr PomperM. AbusederaM. WahlR.L. KinzlerK.W. ZhouS. HusoD.L. VogelsteinB. Bacteriolytic therapy can generate a potent immune response against experimental tumors.Proc. Natl. Acad. Sci. USA200410142151721517710.1073/pnas.040624210115471990
     [Google Scholar]
  23. RobertsN.J. ZhangL. JankuF. CollinsA. BaiR.Y. StaedtkeV. RuskA.W. TungD. MillerM. RoixJ. KhannaK.V. MurthyR. BenjaminR.S. HelgasonT. SzvalbA.D. BirdJ.E. Roy-ChowdhuriS. ZhangH.H. QiaoY. KarimB. McDanielJ. ElpinerA. SahoraA. LachowiczJ. PhillipsB. TurnerA. KleinM.K. PostG. DiazL.A.Jr RigginsG.J. PapadopoulosN. KinzlerK.W. VogelsteinB. BettegowdaC. HusoD.L. VarterasianM. SahaS. ZhouS. Intratumoral injection of Clostridium novyi -NT spores induces antitumor responses.Sci. Transl. Med.20146249249ra11110.1126/scitranslmed.300898225122639
     [Google Scholar]
  24. KrickE.L. SorenmoK.U. RankinS.C. CheongI. KobrinB. ThorntonK. KinzlerK.W. VogelsteinB. ZhouS. DiazL.A. Evaluation of Clostridium novyi–NT spores in dogs with naturally occurring tumors.Am. J. Vet. Res.201273111211810.2460/ajvr.73.1.112
     [Google Scholar]
  25. BettegowdaC. HuangX. LinJ. CheongI. KohliM. SzaboS.A. ZhangX. DiazL.A.Jr VelculescuV.E. ParmigianiG. KinzlerK.W. VogelsteinB. ZhouS. The genome and transcriptomes of the anti-tumor agent Clostridium novyi-NT.Nat. Biotechnol.200624121573158010.1038/nbt125617115055
     [Google Scholar]
  26. KaliaV.C. PatelS.K.S. ChoB.K. WoodT.K. LeeJ.K. Emerging applications of bacteria as antitumor agents.Semin. Cancer Biol.202286Pt 21014102510.1016/j.semcancer.2021.05.01233989734
     [Google Scholar]
  27. WangJ. GhoshD. ManiruzzamanM. Using bugs as drugs: Administration of bacteria-related microbes to fight cancer.Adv. Drug Deliv. Rev.202319711482510.1016/j.addr.2023.11482537075953
     [Google Scholar]
  28. TheysJ. PenningtonO. DuboisL. AnlezarkG. VaughanT. MengeshaA. LanduytW. AnnéJ. BurkeP.J. DûrreP. WoutersB.G. MintonN.P. LambinP. Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo .Br. J. Cancer20069591212121910.1038/sj.bjc.660336717024128
     [Google Scholar]
  29. SandraL. The potential therapeutic gain of radiation-associated gene therapy with the suicide gene cytosine deaminase.Int. J. Radiat. Biol.20007628529310.1080/095530000138628
     [Google Scholar]
  30. WangC.Z. KazmierczakR.A. EisenstarkA. Strains, mechanism, and perspective: Salmonella -based cancer therapy.Int. J. Microbiol.2016201611010.1155/2016/567870227190519
     [Google Scholar]
  31. GanaiS. ArenasR.B. SauerJ.P. BentleyB. ForbesN.S. In tumors Salmonella migrate away from vasculature toward the transition zone and induce apoptosis.Cancer Gene Ther.201118745746610.1038/cgt.2011.1021436868
     [Google Scholar]
  32. SaccheriF. PozziC. AvogadriF. BarozziS. FarettaM. FusiP. RescignoM. Bacteria-induced gap junctions in tumors favor antigen cross-presentation and antitumor immunity.Sci. Transl. Med.201024444ra5710.1126/scitranslmed.300073920702856
     [Google Scholar]
  33. ShiauA.L. ChenC.C. YoY.T. ChuC.Y. WangS.Y. WuC.L. Enhancement of humoral and cellular immune responses by an oral Salmonella choleraesuis vaccine expressing porcine prothymosin α.Vaccine20052348-495563557110.1016/j.vaccine.2005.07.00416125286
     [Google Scholar]
  34. FelgnerS. KocijancicD. PawarV. WeissS. Biomimetic salmonella: A next-generation therapeutic vector?Trends Microbiol.2016241185085210.1016/j.tim.2016.08.00727614692
     [Google Scholar]
  35. LeeC.H. WuC.L. ShiauA.L. Endostatin gene therapy delivered by Salmonella choleraesuis in murine tumor models.J. Gene Med.20046121382139310.1002/jgm.62615468191
     [Google Scholar]
  36. NishikawaH. SatoE. BrionesG. ChenL.M. MatsuoM. NagataY. RitterG. JägerE. NomuraH. KondoS. TawaraI. KatoT. ShikuH. OldL.J. GalánJ.E. GnjaticS. in vivo antigen delivery by aSalmonella typhimurium type III secretion system for therapeutic cancer vaccines.J. Clin. Invest.200611671946195410.1172/JCI2804516794737
     [Google Scholar]
  37. PanthelK. MeinelK.M. Sevil DomènechV.E. GeginatG. LinkemannK. BuschD.H. RüssmannH. Prophylactic anti-tumor immunity against a murine fibrosarcoma triggered by the Salmonella type III secretion system.Microbes Infect.200689-102539254610.1016/j.micinf.2006.07.00416919987
     [Google Scholar]
  38. ZhaoM. YangM. MaH. LiX. TanX. LiS. YangZ. HoffmanR.M. Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice.Cancer Res.200666157647765210.1158/0008‑5472.CAN‑06‑071616885365
     [Google Scholar]
  39. LiX. LiY. WangB. JiK. LiangZ. GuoB. HuJ. YinD. DuY. KopeckoD.J. KalvakolanuD.V. ZhaoX. XuD. ZhangL. Delivery of the co-expression plasmid pEndo-Si-Stat3 by attenuated Salmonella serovar typhimurium for prostate cancer treatment.J. Cancer Res. Clin. Oncol.2013139697198010.1007/s00432‑013‑1398‑023463096
     [Google Scholar]
  40. LiX. LiY. HuJ. WangB. ZhaoL. JiK. GuoB. YinD. DuY. KopeckoD.J. KalvakolanuD.V. ZhaoX. XuD. ZhangL. Plasmid-based E6-specific siRNA and co-expression of wild-type p53 suppresses the growth of cervical cancer in vitro and in vivo .Cancer Lett.2013335124225010.1016/j.canlet.2013.02.03423435374
     [Google Scholar]
  41. LeschnerS. WestphalK. DietrichN. ViegasN. JablonskaJ. LyszkiewiczM. LienenklausS. FalkW. GekaraN. LoessnerH. WeissS. Tumor invasion of Salmonella enterica serovar Typhimurium is accompanied by strong hemorrhage promoted by TNF-α.PLoS One200948e669210.1371/journal.pone.000669219693266
     [Google Scholar]
  42. LeschnerS. WeissS. Salmonella—allies in the fight against cancer.J. Mol. Med.201088876377310.1007/s00109‑010‑0636‑z20526574
     [Google Scholar]
  43. PawelekJ.M. LowK.B. BermudesD. Bacteria as tumour-targeting vectors.Lancet Oncol.20034954855610.1016/S1470‑2045(03)01194‑X12965276
     [Google Scholar]
  44. ZhaoM. GellerJ. MaH. YangM. PenmanS. HoffmanR.M. Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer.Proc. Natl. Acad. Sci. USA200710424101701017410.1073/pnas.070386710417548809
     [Google Scholar]
  45. SeowY. WoodM.J. Biological gene delivery vehicles: Beyond viral vectors.Mol. Ther.200917576777710.1038/mt.2009.4119277019
     [Google Scholar]
  46. ChirulloB. AmmendolaS. LeonardiL. FalciniR. PetrucciP. PistoiaC. VendettiS. BattistoniA. PasqualiP. Attenuated mutant strain of Salmonella Typhimurium lacking the ZnuABC transporter contrasts tumor growth promoting anti-cancer immune response.Oncotarget2015619176481766010.18632/oncotarget.389326158862
     [Google Scholar]
  47. HongJ.W. SongS. ShinJ.H. A novel microfluidic co-culture system for investigation of bacterial cancer targeting.Lab Chip201313153033304010.1039/c3lc50163a23743709
     [Google Scholar]
  48. HayashiK. ZhaoM. YamauchiK. YamamotoN. TsuchiyaH. TomitaK. HoffmanR.M. Cancer metastasis directly eradicated by targeted therapy with a modified Salmonella typhimurium.J. Cell. Biochem.2009106699299810.1002/jcb.2207819199339
     [Google Scholar]
  49. TianY. GuoB. JiaH. JiK. SunY. LiY. ZhaoT. GaoL. MengY. KalvakolanuD.V. KopeckoD.J. ZhaoX. ZhangL. XuD. Targeted therapy via oral administration of attenuated Salmonella expression plasmid-vectored Stat3-shRNA cures orthotopically transplanted mouse HCC.Cancer Gene Ther.201219639340110.1038/cgt.2012.1222555509
     [Google Scholar]
  50. YuL.C.H. WeiS.C. NiY.H. Impact of microbiota in colorectal carcinogenesis: Lessons from experimental models.Intest. Res.201816334635710.5217/ir.2018.16.3.34630090033
     [Google Scholar]
  51. ToleyB.J. ForbesN.S. Motility is critical for effective distribution and accumulation of bacteria in tumor tissue.Integr. Biol.20124216517610.1039/c2ib00091a22193245
     [Google Scholar]
  52. ZhangHY ManJH LiangB ZhouT WangCH LiT Tumor-targeted delivery of biologically active TRAIL protein.Cancer Gene Ther.201017533434310.1038/cgt.2009.76
     [Google Scholar]
  53. XieS. ZhangP. ZhangZ. LiuY. ChenM. LiS. LiX. Bacterial navigation for tumor targeting and photothermally-triggered bacterial ghost transformation for spatiotemporal drug release.Acta Biomater.202113117218410.1016/j.actbio.2021.06.03034171461
     [Google Scholar]
  54. XieS. XiaT. LiS. MoC. ChenM. LiX. Bacteria-propelled microrockets to promote the tumor accumulation and intracellular drug uptake.Chem. Eng. J.202039212378610.1016/j.cej.2019.123786
     [Google Scholar]
  55. MinJ.J. KimH.J. ParkJ.H. MoonS. JeongJ.H. HongY.J. ChoK.O. NamJ.H. KimN. ParkY.K. BomH.S. RheeJ.H. ChoyH.E. Noninvasive real-time imaging of tumors and metastases using tumor-targeting light-emitting Escherichia coli.Mol. Imaging Biol.2008101546110.1007/s11307‑007‑0120‑517994265
     [Google Scholar]
  56. ZhouH. HeZ. WangC. XieT. LiuL. LiuC. SongF. MaY. Intravenous administration is an effective and safe route for cancer gene therapy using the bifidobacterium-mediated recombinant HSV-1 Thymidine Kinase and Ganciclovir.Int. J. Mol. Sci.201617689110.3390/ijms1706089127275821
     [Google Scholar]
  57. GaoX. ZouW. JiangB. XuD. LuoY. XiongJ. YanS. WangY. TangY. ChenC. LiH. QiaoH. WangQ. ZouJ. Experimental study of retention on the combination of bifidobacterium with high-intensity focused ultrasound (HIFU) synergistic substance in tumor tissues.Sci. Rep.201991642310.1038/s41598‑019‑42832‑431015517
     [Google Scholar]
  58. NourM. ArefS. MasoumehH. ShivaM. AminK. How phages overcome the challenges of drug resistant bacteria in clinical infections.Infect. Drug Resist.202013456110.2147/IDR.S23435332021319
     [Google Scholar]
  59. MarziehBakhshinejad Bacteriophages and medical oncology: Targeted gene therapy of cancer.Med. Oncol.20143111010.1007/s12032‑014‑0110‑9
     [Google Scholar]
  60. GhoshD. KohliA.G. MoserF. EndyD. BelcherA.M. Refactored M13 bacteriophage as a platform for tumor cell imaging and drug delivery.ACS Synth. Biol.201211257658210.1021/sb300052u23656279
     [Google Scholar]
  61. MurgasP. BustamanteN. ArayaN. Cruz-GómezS. DuránE. GaeteD. OyarceC. LópezE. HerradaA.A. FerreiraN. PieringerH. LladserA. A filamentous bacteriophage targeted to carcinoembryonic antigen induces tumor regression in mouse models of colorectal cancer.Cancer Immunol. Immunother.201867218319310.1007/s00262‑017‑2076‑x29026949
     [Google Scholar]
  62. JounaidiY. DoloffJ. WaxmanD. Conditionally replicating adenoviruses for cancer treatment.Curr. Cancer Drug Targets20077328530110.2174/15680090778061830117504125
     [Google Scholar]
  63. YanY. XuH. WangJ. WuX. WenW. LiangY. WangL. LiuF. DuX. Inhibition of breast cancer cells by targeting E2F-1 gene and expressing IL15 oncolytic adenovirus.Biosci. Rep.2019397BSR2019038410.1042/BSR2019038431278126
     [Google Scholar]
  64. ZhuW. WeiL. ZhangH. ChenJ. QinX. Oncolytic adenovirus armed with IL-24 Inhibits the growth of breast cancer in vitro and in vivo .J. Exp. Clin. Cancer Res.20123115110.1186/1756‑9966‑31‑5122640485
     [Google Scholar]
  65. SteelJ.C. Di PasqualeG. RamloganC.A. PatelV. ChioriniJ.A. MorrisJ.C. Oral vaccination with adeno-associated virus vectors expressing the Neu oncogene inhibits the growth of murine breast cancer.Mol. Ther.201321368068710.1038/mt.2012.260
     [Google Scholar]
  66. TrepelM. KörbelinJ. SpiesE. HeckmannM.B. HungerA. FehseB. KatusH.A. KleinschmidtJ.A. MüllerO.J. MichelfelderS. Treatment of multifocal breast cancer by systemic delivery of dual-targeted adeno-associated viral vectors.Gene Ther.2015221084084710.1038/gt.2015.5226034897
     [Google Scholar]
  67. WeiC.M. GibsonM. SpearP.G. ScolnickE.M. Construction and isolation of a transmissible retrovirus containing the src gene of Harvey murine sarcoma virus and the thymidine kinase gene of herpes simplex virus type 1.J. Virol.198139393594410.1128/jvi.39.3.935‑944.19816270359
     [Google Scholar]
  68. SieglG. Biology and pathogenicity of autonomous parvoviruses.The Parvoviruses. The Viruses. SpringerBoston, MA198429736210.1007/978‑1‑4684‑8012‑2_8
     [Google Scholar]
  69. LacroixJ. LeuchsB. LiJ. HristovG. DeubzerH.E. KulozikA.E. RommelaereJ. SchlehoferJ.R. WittO. Parvovirus H1 selectively induces cytotoxic effects on human neuroblastoma cells.Int. J. Cancer201012751230123910.1002/ijc.2516820087864
     [Google Scholar]
  70. SiebenM. SchäferP. DinsartC. GalleP.R. MoehlerM. Activation of the human immune system via toll-like receptors by the oncolytic parvovirus H-1.Int. J. Cancer2013132112548255610.1002/ijc.2793823151948
     [Google Scholar]
  71. MuharramG. Le RhunE. LoisonI. WizlaP. RichardA. MartinN. RousselA. BegueA. DevosP. BaranzelliM.C. BonneterreJ. Caillet-FauquetP. StehelinD. Parvovirus H-1 induces cytopathic effects in breast carcinoma-derived cultures.Breast Cancer Res. Treat.20101211233310.1007/s10549‑009‑0451‑919565332
     [Google Scholar]
  72. ConryR.M. WestbrookB. McKeeS. NorwoodT.G. Talimogene laherparepvec: First in class oncolytic virotherapy.Hum. Vaccin. Immunother.201814483984610.1080/21645515.2017.141289629420123
     [Google Scholar]
  73. SchumacherL. RibasA. DissetteV.B. McBrideW.H. MukherjiB. EconomouJ.S. ButterfieldL.H. Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses.J. Immunother.200427319120010.1097/00002371‑200405000‑00003
     [Google Scholar]
  74. ChenY. EmtageP. ZhuQ. FoleyR. MullerW. HittM. GauldieJ. WanY. Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: Enhanced efficacy by cotransduction of gene encoding IL-12.Gene Ther.20018431632310.1038/sj.gt.330139611313806
     [Google Scholar]
  75. PanebiancoC. AndriulliA. PazienzaV. Pharmacomicrobiomics: Exploiting the drug-microbiota interactions in anticancer therapies.Microbiome2018619210.1186/s40168‑018‑0483‑729789015
     [Google Scholar]
  76. ChenB. DuG. GuoJ. ZhangY. Bugs, drugs, and cancer: Can the microbiome be a potential therapeutic target for cancer management?Drug Discov. Today20192441000100910.1016/j.drudis.2019.02.00930818030
     [Google Scholar]
  77. ChowdhuryS. CastroS. CokerC. HinchliffeT.E. ArpaiaN. DaninoT. Programmable bacteria induce durable tumor regression and systemic antitumor immunity.Nat. Med.20192571057106310.1038/s41591‑019‑0498‑z31270504
     [Google Scholar]
  78. BandalaC. Perez-SantosJ.L.M. Lara-PadillaE. Delgado LopezM.G. Anaya-RuizM. Effect of botulinum toxin A on proliferation and apoptosis in the T47D breast cancer cell line.Asian Pac. J. Cancer Prev.201314289189410.7314/APJCP.2013.14.2.891
     [Google Scholar]
  79. ZhangJ. WeiH. GuoX. HuM. GaoF. LiL. ZhangS. Functional verification of the diphtheria toxin A gene in a recombinant system.J. Anim. Sci. Biotechnol.2012312910.1186/2049‑1891‑3‑2923062032
     [Google Scholar]
  80. LiM. ZhouH. YangC. WuY. ZhouX. LiuH. WangY. Bacterial outer membrane vesicles as a platform for biomedical applications: An update.J. Control. Release202032325326810.1016/j.jconrel.2020.04.03132333919
     [Google Scholar]
  81. KimO.Y. ParkH.T. DinhN.T.H. ChoiS.J. LeeJ. KimJ.H. LeeS.W. GhoY.S. Bacterial outer membrane vesicles suppress tumor by interferon-γ-mediated antitumor response.Nat. Commun.20178162610.1038/s41467‑017‑00729‑828931823
     [Google Scholar]
  82. Kaparakis-LiaskosM. FerreroR.L. Immune modulation by bacterial outer membrane vesicles.Nat. Rev. Immunol.201515637538710.1038/nri383725976515
     [Google Scholar]
  83. ZhuX.H. DuJ.X. ZhuD. RenS.Z. ChenK. ZhuH.L. Recent research on methods to improve tumor hypoxia environment.Oxid. Med. Cell. Longev.2020202011810.1155/2020/572125833343807
     [Google Scholar]
  84. Bressuire-IsoardC. BroussolleV. CarlinF. Sporulation environment influences spore properties in Bacillus: Evidence and insights on underlying molecular and physiological mechanisms.FEMS Microbiol. Rev.201842561462610.1093/femsre/fuy02129788151
     [Google Scholar]
  85. DucL.H. HongH.A. FairweatherN. RiccaE. CuttingS.M. Bacterial spores as vaccine vehicles.Infect. Immun.20037152810281810.1128/IAI.71.5.2810‑2818.2003
     [Google Scholar]
  86. BarbéS. Van MellaertL. AnnéJ. The use of clostridial spores for cancer treatment.J. Appl. Microbiol.2006101357157810.1111/j.1365‑2672.2006.02886.x16907807
     [Google Scholar]
  87. SoojeongPark HuangXiaoke LarsonAndrew C. Branched gold nanoparticle coating of *Clostridium novyi*-NT spores for CT-guided intratumoral injection.Small201613160272210.1002/smll.201602722
     [Google Scholar]
  88. PanF. ChenZ. LiY. Novel insights into the role of Clostridium novyi-NT related combination bacteriolytic therapy in solid tumors.Oncol. Lett.202021110.3892/ol.2020.12371
     [Google Scholar]
  89. SiqingJanku RaviMurthy KarpDaniel D. HongDavid S. MariaTsimberidou Apostolia GillisonMaura L. AbhaAdat AnjaliRaina GregCall BrentKreider DavidTung MaryVarterasian 383 First-in-man clinical trial of intratumoral injection of *Clostridium novyi*-NT spores in combination with pembrolizumab in patients with treatment-refractory advanced solid tumors.J. Immunother. Cancer2020810.1136/jitc‑2020‑SITC2020.0383
     [Google Scholar]
  90. PumD. Toca-HerreraJ. SleytrU. S-layer protein self-assembly.Int. J. Mol. Sci.20131422484250110.3390/ijms1402248423354479
     [Google Scholar]
  91. MaderC. HuberC. MollD. SleytrU.B. SáraM. Interaction of the crystalline bacterial cell surface layer protein SbsB and the secondary cell wall polymer of Geobacillus stearothermophilus PV72 assessed by real-time surface plasmon resonance biosensor technology.J. Bacteriol.200418661758176810.1128/JB.186.6.1758‑1768.200414996807
     [Google Scholar]
  92. BuseJ. El-AneedA. Properties, engineering and applications of lipid-based nanoparticle drug-delivery systems: Current research and advances.Nanomedicine2010581237126010.2217/nnm.10.10721039200
     [Google Scholar]
  93. UcisikM.H. KüpcüS. DebreczenyM. SchusterB. SleytrU.B. S-layer coated emulsomes as potential nanocarriers.Small20139172895290410.1002/smll.20120311623606662
     [Google Scholar]
  94. UcisikM.H. KüpcüS. SchusterB. SleytrU.B. Characterization of CurcuEmulsomes: Nanoformulation for enhanced solubility and delivery of curcumin.J. Nanobiotechnology20131113710.1186/1477‑3155‑11‑3724314310
     [Google Scholar]
  95. MaderC. KüpcüS. SleytrU.B. SáraM. S-layer-coated liposomes as a versatile system for entrapping and binding target molecules.Biochim. Biophys. Acta Biomembr.20001463114215010.1016/S0005‑2736(99)00190‑X10631303
     [Google Scholar]
  96. JeonO. PowellC. AhmedS.M. AlsbergE. Biodegradable, photocrosslinked alginate hydrogels with independently tailorable physical properties and cell adhesivity.Tissue Eng. Part A20101692915292510.1089/ten.tea.2010.009620486798
     [Google Scholar]
  97. SleytrU.B. HuberC. IlkN. PumD. SchusterB. EgelseerE.M. S-layers as a tool kit for nanobiotechnological applications.FEMS Microbiol. Lett.2007267213114410.1111/j.1574‑6968.2006.00573.x17328112
     [Google Scholar]
  98. IlkN. EgelseerE.M. Ferner-OrtnerJ. KüpcüS. PumD. SchusterB. SleytrU.B. Surfaces functionalized with self-assembling S-layer fusion proteins for nanobiotechnological applications.Colloids Surf. A Physicochem. Eng. Asp.20083211-316316710.1016/j.colsurfa.2007.12.038
     [Google Scholar]
  99. SuriS.S. FenniriH. SinghB. Nanotechnology-based drug delivery systems.J. Occup. Med. Toxicol.2007211610.1186/1745‑6673‑2‑1618053152
     [Google Scholar]
  100. WetzerB. PumD. SleytrU.B. S-layer stabilized solid support lipid bilayers.J. Struct. Biol.1997119212312810.1006/jsbi.1997.38679245752
     [Google Scholar]
  101. KollerV.J. DirschV.M. BeresH. DonathO. ReznicekG. LubitzW. KudelaP. Modulation of bacterial ghosts – induced nitric oxide production in macrophages by bacterial ghost-delivered resveratrol.FEBS J.201328051214122510.1111/febs.1211223289719
     [Google Scholar]
  102. LangemannT. KollerV.J. MuhammadA. KudelaP. MayrU.B. LubitzW. The bacterial ghost platform system.Bioeng. Bugs20101532633610.4161/bbug.1.5.1254021326832
     [Google Scholar]
  103. GaneshpurkarA. GaneshpurkarA. PandeyV. AgnihotriA. BansalD. DubeyN. Harnessing the potential of bacterial ghost for the effective delivery of drugs and biotherapeutics.Int. J. Pharm. Investig.2014411410.4103/2230‑973X.12773324678455
     [Google Scholar]
  104. BrownL. WolfJ.M. Prados-RosalesR. CasadevallA. Through the wall: extracellular vesicles in Gram-positive bacteria, mycobacteria and fungi.Nat. Rev. Microbiol.2015131062063010.1038/nrmicro348026324094
     [Google Scholar]
  105. TakeoK. UesakaI. UehiraK. NishiuraM. Fine structure of Cryptococcus neoformans grown in vitro as observed by freeze-etching.J. Bacteriol.197311331442144810.1128/jb.113.3.1442‑1448.19734347973
     [Google Scholar]
  106. KlimentováJ. StulíkJ. Methods of isolation and purification of outer membrane vesicles from gram-negative bacteria.Microbiol. Res.20151701910.1016/j.micres.2014.09.00625458555
     [Google Scholar]
  107. SonsireA. CaridadZ. ArmandoA. SarmientoM.E. FerroV.A. EinarR. CampaC. Bacterial outer membrane vesicles and vaccine applications.Front. Immunol.2014512110.3389/fimmu.2014.00121
     [Google Scholar]
  108. Avila-CalderónE.D. Lopez-MerinoA. JainN. PeraltaH. López-VillegasE.O. SriranganathanN. BoyleS.M. WitonskyS. Contreras-RodríguezA. Characterization of outer membrane vesicles from Brucella melitensis and protection induced in mice.Clin. Dev. Immunol.2012201211310.1155/2012/35249322242036
     [Google Scholar]
  109. SargentJ. BellG. McEvoyL. TocherD. EstevezA. Recent developments in the essential fatty acid nutrition of fish.Aquaculture19991771-419119910.1016/S0044‑8486(99)00083‑6
     [Google Scholar]
  110. BlancV. MesaR. SacoM. LavillaS. PratsG. MiróE. NavarroF. CortésP. LlagosteraM. ESBL- and plasmidic class C β-lactamase-producing E. coli strains isolated from poultry, pig and rabbit farms.Vet. Microbiol.20061183-429930410.1016/j.vetmic.2006.08.002
     [Google Scholar]
  111. PérezK. OsorioM. HernándezJ. CarrA. FernándezL.E. NGcGM3/VSSP vaccine as treatment for melanoma patients.Hum. Vaccin. Immunother.2013961237124010.4161/hv.2411523442598
     [Google Scholar]
  112. MousaviT. Sattari SaraviS. ValadanR. HaghshenasM.R. RafieiA. JafarpourH. ShamshirianA. Different types of adjuvants in prophylactic and therapeutic human papillomavirus vaccines in laboratory animals: A systematic review.Arch. Virol.2020165226328410.1007/s00705‑019‑04479‑431802228
     [Google Scholar]
  113. KhanA.N.M.N.H. EmmonsT.R. MagnerW.J. AlqassimE. SingelK.L. RicciutiJ. EngK.H. OdunsiK. TomasiT.B. LeeK. AbramsS.I. MesaC. SegalB.H. VSSP abrogates murine ovarian tumor-associated myeloid cell-driven immune suppression and induces M1 polarization in tumor-associated macrophages from ovarian cancer patients.Cancer Immunol. Immunother.202271102355236910.1007/s00262‑022‑03156‑x
     [Google Scholar]
  114. EstevezF. CarrA. SolorzanoL. ValienteO. MesaC. BarrosoO. Victoriano SierraG. FernandezL.E. Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP).Vaccine1999181-219019710.1016/S0264‑410X(99)00219‑410501249
     [Google Scholar]
  115. MulensV. de la TorreA. MarinelloP. RodríguezR. CardosoJ. DíazR. O´FarrillM. MaciasA. ViadaC. SaurezG. CarrA. CrombetT. MazorraZ. PerezR. FernándezL.E. Immunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients.Hum. Vaccin.20106973674410.4161/hv.6.9.12571
     [Google Scholar]
  116. OsorioM. OsorioM. Gracia HernandezJ. De la TorreA. Cepeda Car Fernandez Avila Rodríguez AvilaY. RodríguezM. FernandezL.E. Effect of vaccination with N-glycolyl GM3/VSSP vaccine by subcutaneous injection in patients with advanced cutaneous melanoma.Cancer Manag. Res.2012434134510.2147/CMAR.S2261723055778
     [Google Scholar]
  117. Bequet-RomeroM. MoreraY. Ayala-ÁvilaM. AncizarJ. SoriaY. BlancoA. Suárez-AlbaJ. GavilondoJ.V. CIGB-247: A VEGF-based therapeutic vaccine that reduces experimental and spontaneous lung metastasis of C57Bl/6 and BALB/c mouse tumors.Vaccine201230101790179910.1016/j.vaccine.2012.01.006
     [Google Scholar]
  118. AguilarF.F. BarrancoJ.J. FuentesE.B. AguileraL.C. SáezY.L. SantanaM.D.C. VázquezE.P. BakerR.B. AcostaO.R. PérezH.G. NietoG.G. Very small size proteoliposomes (VSSP) and Montanide combination enhance the humoral immuno response in a GnRH based vaccine directed to prostate cancer.Vaccine201230466595659910.1016/j.vaccine.2012.08.02022921738
     [Google Scholar]
  119. FernándezA. OliverL. AlvarezR. HernándezA. RaymondJ. FernándezL.E. MesaC. Very small size proteoliposomes abrogate cross-presentation of tumor antigens by myeloid-derived suppressor cells and induce their differentiation to dendritic cells.J. Immunother. Cancer201421510.1186/2051‑1426‑2‑524829762
     [Google Scholar]
  120. BrownA.J. XIX.—The chemical action of pure cultivations of bacterium aceti.J. Chem. Soc. Trans.188649017218710.1039/CT8864900172
     [Google Scholar]
  121. RehmB.H.A. Bacterial polymers: Biosynthesis, modifications and applications.Nat. Rev. Microbiol.20108857859210.1038/nrmicro235420581859
     [Google Scholar]
  122. YorkG.M. JunkerB.H. StubbeJ. SinskeyA.J. Accumulation of the PhaP phasin of Ralstonia eutropha is dependent on production of polyhydroxybutyrate in cells.J. Bacteriol.2001183144217422610.1128/JB.183.14.4217‑4226.200111418562
     [Google Scholar]
  123. SteinbüchelA. Perspectives for biotechnological production and utilization of biopolymers: Metabolic engineering of polyhydroxyalkanoate biosynthesis pathways as a successful example.Macromol. Biosci.20011112410.1002/1616‑5195(200101)1:1<1::AID‑MABI1>3.0.CO;2‑B
     [Google Scholar]
  124. FarjadianF. MoghoofeiM. MirkianiS. GhasemiA. RabieeN. HadifarS. BeyzaviA. KarimiM. HamblinM.R. Bacterial components as naturally inspired nano-carriers for drug/gene delivery and immunization: Set the bugs to work?Biotechnol. Adv.201836496898510.1016/j.biotechadv.2018.02.01629499341
     [Google Scholar]
  125. HayI.D. WangY. MoradaliM.F. RehmanZ.U. RehmB.H.A. Genetics and regulation of bacterial alginate production.Environ. Microbiol.201416102997301110.1111/1462‑2920.12389
     [Google Scholar]
  126. MoebusK. SiepmannJ. BodmeierR. Alginate–poloxamer microparticles for controlled drug delivery to mucosal tissue.Eur. J. Pharm. Biopharm.2009721425310.1016/j.ejpb.2008.12.00419126428
     [Google Scholar]
  127. MatricardiP. OnoratiI. CovielloT. AlhaiqueF. Drug delivery matrices based on scleroglucan/alginate/borax gels.Int. J. Pharm.20063161-2212810.1016/j.ijpharm.2006.02.02416554128
     [Google Scholar]
  128. JayantR.D. McShaneM.J. SrivastavaR. Polyelectrolyte-coated alginate microspheres as drug delivery carriers for dexamethasone release.Drug Deliv.200916633134010.1080/1071754090303112619606947
     [Google Scholar]
  129. MartínezA. AranaP. FernándezA. OlmoR. TeijónC. BlancoM.D. Synthesis and characterisation of alginate/chitosan nanoparticles as tamoxifen controlled delivery systems.J. Microencapsul.201330439840810.3109/02652048.2012.74674723489017
     [Google Scholar]
  130. MartínM.J. CalpenaA.C. FernándezF. MallandrichM. GálvezP. ClaresB. Development of alginate microspheres as nystatin carriers for oral mucosa drug delivery.Carbohydr. Polym.201511714014910.1016/j.carbpol.2014.09.032
     [Google Scholar]
  131. MoonR.J. MartiniA. NairnJ. SimonsenJ. YoungbloodJ. Cellulose nanomaterials review: Structure, properties and nanocomposites.Chem. Soc. Rev.20114073941399410.1039/c0cs00108b
     [Google Scholar]
  132. LopesC.A. de SouzaS.F. de OlyveiraG.M. CostaL.M.M. BrandãoC.V.S. NarineS.S. Bacterial nanocellulose for medical implants.Advances in Natural PolymersSpringerBerlin, Heidelberg.201233735910.1007/978‑3‑642‑20940‑6_10
     [Google Scholar]
  133. MüllerA. NiZ. HesslerN. WesargF. MüllerF.A. KralischD. FischerD. The biopolymer bacterial nanocellulose as drug delivery system: investigation of drug loading and release using the model protein albumin.J. Pharm. Sci.2013102257959210.1002/jps.2338523192666
     [Google Scholar]
  134. NumataY. MazzarinoL. BorsaliR. A slow-release system of bacterial cellulose gel and nanoparticles for hydrophobic active ingredients.Int. J. Pharm.20154861-221722510.1016/j.ijpharm.2015.03.06825840273
     [Google Scholar]
  135. Van BruntJ. More to hyaluronic acid than meets the eye.Nat. Biotechnol.19864978078210.1038/nbt0986‑780
     [Google Scholar]
  136. JinY-J. UbonvanT. KimD-D. Hyaluronic acid in drug delivery systems.J. Pharm. Investig.201040spc334310.4333/KPS.2010.40.S.033
     [Google Scholar]
  137. MattheolabakisG. MilaneL. SinghA. AmijiM.M. Hyaluronic acid targeting of CD44 for cancer therapy: From receptor biology to nanomedicine.J. Drug Target.2015237-860561810.3109/1061186X.2015.105207226453158
     [Google Scholar]
  138. ChoiK. JangM. KimJ.H. AhnH.J. Tumor-specific delivery of siRNA using supramolecular assembly of hyaluronic acid nanoparticles and 2b RNA-binding protein/siRNA complexes.Biomaterials201435257121713210.1016/j.biomaterials.2014.04.09624854094
     [Google Scholar]
  139. Portilla-AriasJ.A. CamargoB. García-AlvarezM. de IlarduyaA.M. Muñoz-GuerraS. Nanoparticles made of microbial poly(γ-glutamate)s for encapsulation and delivery of drugs and proteins.J. Biomater. Sci. Polym. Ed.2009207-81065107910.1163/156856209X444420
     [Google Scholar]
  140. WangX. UtoT. AkagiT. AkashiM. BabaM. Poly(γ-glutamic acid) nanoparticles as an efficient antigen delivery and adjuvant system: Potential for an AIDS vaccine.J. Med. Virol.2008801111910.1002/jmv.21029
     [Google Scholar]
  141. GonçalvesAna Catarina Leite InêsPereira JoséOliveira Maria BarbosaMário A. Macrophage response to chitosan/poly-(γ-glutamic acid) nanoparticles carrying an anti-inflammatory drug.J. Mater. Sci. Mater. Med.20152616710.1007/s10856‑015‑5496‑1
     [Google Scholar]
  142. OkamotoS. YoshiiH. MatsuuraM. KojimaA. IshikawaT. AkagiT. AkashiM. TakahashiM. YamanishiK. MoriY. Poly-γ-glutamic acid nanoparticles and aluminum adjuvant used as an adjuvant with a single dose of Japanese encephalitis virus- like particles provide effective protection from Japanese encephalitis virus.Clin. Vaccine Immunol.2012191172210.1128/CVI.05412‑1122089248
     [Google Scholar]
  143. ShimaS. SakaiH. Poly- l -lysine produced by streptomyces. Part III. Chemical studies.Agric. Biol. Chem.198145112503250810.1080/00021369.1981.10864930
     [Google Scholar]
  144. ShihI. ShenM. VanY. Microbial synthesis of poly(ε-lysine) and its various applications.Bioresour. Technol.20069791148115910.1016/j.biortech.2004.08.01216551535
     [Google Scholar]
  145. EomK.D. ParkS.M. TranH.D. KimM.S. YuR.N. YooH. Dendritic α,ε-poly(L-lysine)s as delivery agents for antisense oligonucleotides.Pharm. Res.20072481581158910.1007/s11095‑006‑9231‑y17373579
     [Google Scholar]
  146. ZhangL. ZhouY. LiG. ZhaoY. GuX. YangY. Nanoparticle mediated controlled delivery of dual growth factors.Sci. China Life Sci.201457225626210.1007/s11427‑014‑4606‑524430559
     [Google Scholar]
  147. WangR. ZhouB. XuD. XuH. LiangL. FengX. OuyangP. ChiB. Antimicrobial and biocompatible ε-polylysine–γ-poly(glutamic acid)–based hydrogel system for wound healing.J. Bioact. Compat. Polym.201631324225910.1177/0883911515610019
     [Google Scholar]
  148. TogoY. TakahashiK. SaitoK. KisoH. HuangB. TsukamotoH. HyonS.H. BesshoK. Aldehyded dextran and ε -poly(L-lysine) hydrogel as nonviral gene carrier.Stem Cells Int.201320131510.1155/2013/63437924027586
     [Google Scholar]
  149. GujratiV. KimS. KimS-H. MinJ.J. ChoyH.E. KimS.C. JonS. Bioengineered bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy.ACS Nano2014821525153710.1021/nn405724x
     [Google Scholar]
  150. LouX. ChenZ. HeZ. SunM. SunJ. Bacteria-mediated synergistic cancer therapy: Small microbiome has a big hope.Nano-Micro Lett.20211313710.1007/s40820‑020‑00560‑934138211
     [Google Scholar]
  151. LuY. MeiN. YingY. WangD. LiX. ZhaoY. ZhuY. ShenS. YinB. Bacteria-based nanoprobes for cancer therapy.Int. J. Nanomedicine20241975978510.2147/IJN.S43816438283198
     [Google Scholar]
  152. AllemailemK.S. Innovative approaches of engineering tumor-targeting bacteria with different therapeutic payloads to fight cancer: A smart strategy of disease management.Int. J. Nanomedicine2021168159818410.2147/IJN.S33827234938075
     [Google Scholar]
  153. AfkhamiH. YarahmadiA. BostaniS. YarianN. HaddadM.S. LesaniS.S. AghaeiS.S. ZolfaghariM.R. Converging frontiers in cancer treatment: The role of nanomaterials, mesenchymal stem cells, and microbial agents—challenges and limitations.Discover Oncology202415181810.1007/s12672‑024‑01590‑039707033
     [Google Scholar]
  154. AttarM. ShamsabadiF.T. SoltaniA. JoghataeiM.T. khandooziS.R. TeimourianS. ShahbaziM. Erfani-MoghadamV. Development and characterization of paclitaxel-loaded MF59 nano-emulsion for breast cancer therapy.Bionanoscience20241432730273810.1007/s12668‑024‑01501‑1
     [Google Scholar]
  155. GhanbarikondoriP. AliakbariR.B.S. SaberianE. JenčaA. PetrášováA. JenčováJ. KhayaviA.A. Enhancing cisplatin delivery via liposomal nanoparticles for oral cancer treatment.Indian J. Clin. Biochem.202410.1007/s12291‑024‑01239‑3
     [Google Scholar]
  156. MaedaH. NakamuraH. FangJ. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo .Adv. Drug Deliv. Rev.2013651717910.1016/j.addr.2012.10.00223088862
     [Google Scholar]
  157. PatilY. SadhukhaT. MaL. PanyamJ. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance.J. Control. Release20091361212910.1016/j.jconrel.2009.01.02119331851
     [Google Scholar]
  158. SharmaP. AllisonJ.P. The future of immune checkpoint therapy.Science20153486230566110.1126/science.aaa817225838373
     [Google Scholar]
  159. SivanA. CorralesL. HubertN. WilliamsJ.B. Aquino-MichaelsK. EarleyZ.M. BenyaminF.W. Man LeiY. JabriB. AlegreM.L. ChangE.B. GajewskiT.F. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy.Science201535062641084108910.1126/science.aac425526541606
     [Google Scholar]
/content/journals/ddl/10.2174/0122103031324481250609130704
Loading
Microbial-Based Nanoparticle for Cancer Therapy: Opportunities and Challenges
Drug Deliv Lett 15, 369 (2025); https://doi.org/10.2174/0122103031324481250609130704
/content/journals/ddl/10.2174/0122103031324481250609130704
/content/journals/ddl/10.2174/0122103031324481250609130704
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): cancer therapy; immunotherapy, clinical practice; Microbial nanoparticles; nanotechnology; tumor targeting

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test